Today Celadon announced its Interim Results for the six months ended 30 June 2022, a period of considerable development and growth for the company. Highlights include: – The completion of seven harvests of high THC cannabis – Formally requesting that the MHRA schedule an inspection of our facility for our GMP licence – The commencement …
There has been an excellent article published in The Times today about the groundbreaking 5,000 patient trial by one of our subsidiary companies LVL Health Medical Cannabis Clinic to study the use of medicinal cannabis to treat chronic pain. Celadon Pharmaceuticals Plc is getting ready to become the provider of medical-grade cannabis for the trial …
Celadon is this morning delighted to announce its admission to the London Stock Exchange AIM market, raising £8.5m and bringing the total raise in the past year to ~£20m. Our goal is to become the provider and partner of choice for researching and producing pharmaceutical-grade cannabinoid-based medicines. We have built an integrated supply chain and …
Input your search keywords and press Enter.